That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...
One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...
Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...
which was acquired by GSK when it took over Tesaro in a $5.1 billion deal agreed in 2019, along with PARP inhibitor Zejula (niraparib). There are a number of other TIM-3 targeting drugs coming ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...
Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...
The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback